• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Astrocyte Marker GFAP Identifies Elevated Cognitive Decline Risk Across Alzheimer Continuum

by
November 19, 2026
in Health
Reading Time: 3 mins read
0
Astrocyte Marker GFAP Identifies Elevated Cognitive Decline Risk Across Alzheimer Continuum

Astrocyte Marker GFAP Identifies Elevated Cognitive Decline Risk Across Alzheimer Continuum

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Elevated levels of plasma glial fibrillary acidic protein significantly modulate the relationship between phosphorylated tau at threonine 217 and clinical progression across the Alzheimer’s disease continuum, according to a multi-cohort study. Investigators found that individuals exhibiting concurrent elevations in both plasma markers experienced worse baseline cognitive performance, faster longitudinal cognitive decline, and a heightened risk of clinical worsening compared to those positive only for p-tau217.

While plasma p-tau217 serves as a robust biomarker of Alzheimer’s disease pathology and disease progression, individuals who test positive for this marker frequently display substantial clinical heterogeneity. This variability indicates that additional modifying biological processes shape individual clinical trajectories. To address this question, researchers evaluated whether plasma glial fibrillary acidic protein, an indicator of astrocyte reactivity, modifies the association between elevated p-tau217 and cognitive decline.

The investigation analyzed 3,505 individuals spanning the aging and Alzheimer’s disease spectrum drawn from six independent cohorts. For each participant, baseline evaluations included amyloid-beta positron emission tomography, plasma glial fibrillary acidic protein, plasma p-tau217, and the Clinical Dementia Rating Sum of Boxes. Study participants were subsequently classified into four distinct biomarker groups determined by their positivity status for glial fibrillary acidic protein and p-tau217.

To evaluate clinical patterns, the research team examined cross-sectional associations with cognitive severity using linear regression and analysis of covariance. Five-year longitudinal cognitive trajectories were evaluated using linear mixed-effects models. Investigators further conducted variance partitioning analyses to decompose the proportion of biomarker-attributable variance in individual annual rates of change on the Clinical Dementia Rating Sum of Boxes, while time to clinical worsening—defined as an increase of at least 0.5 points on the scale—was assessed through Kaplan–Meier survival analysis and Cox proportional hazards regression.

Longitudinal modeling demonstrated that individuals with co-elevated plasma glial fibrillary acidic protein and p-tau217 exhibited an annual progression rate on the Clinical Dementia Rating Sum of Boxes that was 62 percent higher than that observed in individuals positive for p-tau217 alone (p = 0.008). In survival analyses, co-elevation was associated with an increased hazard of clinical worsening (hazard ratio 1.28; 95% confidence interval 1.01 to 1.61). Variance partitioning revealed that the interaction between glial fibrillary acidic protein and p-tau217 accounted for 68.6 percent of the biomarker-related variance in longitudinal cognitive decline, markedly exceeding the independent contributions of p-tau217 at 25.3 percent and glial fibrillary acidic protein at 1.1 percent.

The study concluded that astrocyte reactivity is associated with greater cognitive impairment and accelerated clinical decline among individuals with elevated p-tau217, providing prognostic stratification within the p-tau217-positive population. Combining plasma measurements of glial fibrillary acidic protein and p-tau217 offers measurable value for identifying individuals at higher risk of progression, with implications for clinical risk stratification and trial enrichment.

Subject of Research: Astrocyte reactivity and cognitive decline risk in Alzheimer's disease

Article Title: Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum

Article References: Bellaver, B., Povala, G., Ferreira, P. C. L., Leffa, D. T., Bauer-Negrini, G., Ferrari-Souza, J. P., Lussier, F. Z., Amaral, L., Tuma, R. L., Oliveira Franco, A. D., Karim, H. T., Hong, C. H., Roh, H. W., Rahmouni, N., Macedo, A., Therriault, J., Servaes, S., Stevenson, J., Trudel, L., … Foroud, T. (2026). Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-026-00995-5

Image Credits: AI Generated

DOI: 10.1186/s13024-026-00995-5

Keywords: Alzheimer's disease, plasma p-tau217, plasma GFAP, astrocyte reactivity, cognitive decline, Clinical Dementia Rating, CDR-SB, biomarkers, amyloid-beta PET, longitudinal progression, prognostic stratification, clinical trial enrichment, Cox proportional hazards, linear mixed-effects models, variance partitioning, HEAD study

News Source: Cassandra Pierce. (November 19, 2026). Astrocyte Marker GFAP Identifies Elevated Cognitive Decline Risk Across Alzheimer Continuum. Scienmag.

Tags: Alzheimer's diseaseamyloid-beta PETastrocyte reactivitybiomarkersCDR-SBClinical Dementia Ratingclinical trial enrichmentCognitive DeclineCox proportional hazardsHEAD studylinear mixed-effects modelslongitudinal progressionplasma GFAPplasma p-tau217prognostic stratificationvariance partitioning
Share12Tweet7Share2ShareShareShare1

Related Posts

88 Percent of Ghanaian Women Use Disposable Sanitary Pads

88 Percent of Ghanaian Women Use Disposable Sanitary Pads

November 19, 2026
Severe Ethnic Disparities in Peruvian Infant Mortality Persist Across Wealth Strata

Severe Ethnic Disparities in Peruvian Infant Mortality Persist Across Wealth Strata

November 19, 2026

Fixation Beat Recurrence During Left Bundle Branch Pacing Varies by Indication

November 19, 2026

Unimproved Sanitation and Child Waste Disposal Correlate With Reported Typhoid Fever

November 19, 2026

POPULAR NEWS

  • Municipal Leaders Rely on Tech Champions Lacking Training and Compensation

    Municipal Leaders Rely on Tech Champions Lacking Training and Compensation

    29 shares
    Share 12 Tweet 7
  • Virtual Reality Cognitive Games Show Preliminary Promise for Stroke Recovery Outcomes

    29 shares
    Share 12 Tweet 7
  • Alzheimer’s Risk Gene SORL1 Deficiency Impairs Mitochondrial Function in Human Microglia

    29 shares
    Share 12 Tweet 7
  • Optimized Streptozotocin Delivery Regimen Improves Sporadic Alzheimer’s Disease Modeling in Rodents

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

88 Percent of Ghanaian Women Use Disposable Sanitary Pads

Severe Ethnic Disparities in Peruvian Infant Mortality Persist Across Wealth Strata

Fixation Beat Recurrence During Left Bundle Branch Pacing Varies by Indication

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.